Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium

Huntington Beach, California and Amsterdam (ots/PRNewswire)
-- Agendia, a world leader in molecular cancer diagnostics,
announced today that it will be presenting six studies focusing on
MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium
(SABCS), one of the premiere conferences in breast cancer research
worldwide. The SABCS will take place December 9-13, at the Henry B.
Gonzalez Convention Center in San Antonio, Texas, USA.

Agendia's studies to be presented at the SABCS further establish
the broad predictive and prognostic power of MammaPrint, the only
FDA-cleared breast cancer recurrence test available to patients and
physicians. Conference attendees can meet the Agendia team at booth
#556.

Study results will be discussed at the following sessions:

Date: Thursday, December 10, 2009

Time: 5:30 pm - 7:30 pm

Poster presentation (102)

Combining Genomic Profiling (70 Gene-MammaPrint) with Nodal
Status Allows to Classify Patients with Primary Breast Cancer and
Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups
That Could Help Tailor Treatment Strategies

Saghatchian M, Mook S, Pruneri G, Viale G, Glas A, Eekhout I,
Delaloge S, van 't Veer L. Institut Gustave Roussy, Villejuif,
France; Netherlands Cancer Institute, Amsterdam, The Netherlands;
European Institute of Oncology, Milan, Italy; Agendia BV, Amsterdam,
The Netherlands.

Date: Friday, December 11, 2009

Time: 7 am - 9 am

Poster presentation (2026)

Basal-, Luminal-, and HER2- Molecular Subtype, and the MammaPrint
70-Gene Signature as Predictors of Response to Neoadjuvant
Chemotherapy (NCT) with Docetaxel, Doxorubicin, Cyclophosphamide
(TAC), or AC and Nab-Paclitaxel and Carboplatin +/- Trastuzumab in
Patients (pts) with Stage II-III and Inflammatory Breast Cancer (BC)

Somlo G, Lau S, Frankel P, Garberoglio C, Kruper L, Yen Y, Luu T,
Hurria A, Chung CT, Mortimer J, Yim J, Paz IBe, Krijgsman O, Delahaye
L, Stork-Sloots L, Bender R. City of Hope Comprehensive Cancer
Center, Duarte, CA; Agendia BV, Amsterdam, The Netherlands; Agenda,
Inc., Huntington Beach, CA.

Date: Saturday, December 12, 2009

Time: 7 am - 9 am

Poster presentation (4049)

The 70-Gene Profile (MammaPrint) Is an Independent Predictor
of Breast Cancer Specific Survival for Women 65 Years of Age or Older

Bedard PL, Mook S, Knauer M, Durbecq V, Bernard-Marty C, Glas AM,
Cardoso F, van 't Veer LJ. Jules Bordet Institute, Brussels, Belgium;
Netherlands Cancer Institute, Amsterdam, The Netherlands; TRANSBIG
Consortium, Brussels, Belgium; Agendia BV, Amsterdam, The Netherlands

Date: Sunday, December 13, 2009

Time: 7 am - 8:30am

Poster presentation (6131)

Molecular Subtype Profile Reveals Therapy Predictive Power

de Snoo FA, Krijgsman O, Roepman P, Bender RA, Glas AM. Agendia
BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA..

Date: Sunday, December 13, 2009

Time: 7 am - 8:30am

Poster presentation (6146)

Biological Functions of Genes in the 70-Gene MammaPrint Tumor
Expression Profile Reflect Molecular Mechanism of Tumor Metastasis

Glas AM, Tian S, Roepman P, Krijgsman O, Van 't Veer LJ, de Snoo
F. Agendia BV, Amsterdam, The Netherlands; The Netherlands Cancer
Institute, Amsterdam, The Netherlands.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA
clearance under the in vitro diagnostic multivariate index assay
(IVDMIA) guidelines requires clinical and analytical validation and
reporting systems to ensure patient safety issues are addressed.
Highly accurate, MammaPrint identifies patients with early metastasis
risk - patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test results provide doctors with
a clear rationale to assess the benefit of chemotherapy in addition
to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited
service laboratory. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous
FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting-edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets three products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. Agendia is based in Huntington Beach, California, and
in Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media contacts: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com. Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, vdelva@ricochetpr.com